CTVA Corteva 10-Q 2026-09-30 section summaries

Corteva (CTVA) — Q3 and nine months ended September 30, 2026

Consolidated results

Q3 sales declined 6.1%, while 9M sales increased 1.9%. Q3 results were pressured by weaker segment performance and higher separation costs ($99M versus $7M) and interest expense ($75M versus $46M). For 9M, separation costs were $230M versus $7M; other expense was $266M versus $95M of other income in 2025. Nine-month results also included $278M of excluded significant charges, including a $120M litigation settlement and $158M of net restructuring and asset-related charges.

Segment performance

Nine-month revenue and EBITDA growth came from Seed; Crop Protection revenue was slightly lower and EBITDA essentially flat. Q3 weakness affected both segments, particularly Crop Protection, while Seed remained seasonally loss-making.

Product-line revenue

Nine-month revenue was $5,848M for Corn ($5,616M prior year), $1,723M for Soybean ($1,714M), $622M for other oilseeds ($550M), $267M for Other Seed ($281M), $2,690M for Herbicides ($2,668M), and $768M for Fungicides ($868M). Latin America Crop Protection was a notable pressure point: Q3 revenue was $555M versus $770M and 9M revenue was $1,356M versus $1,545M.

Cash flow and balance sheet

Operating cash outflow reflected $1,567M of pension/OPEB contributions versus $110M and a $3,130M decline in deferred revenue versus $2,824M. Corteva contributed $1,460M to its principal U.S. pension plan. Financing provided $3,989M, including a $3,264M net increase in short-term borrowings and $2,660M of debt proceeds; the company repurchased $500M of shares and paid $361M in dividends.

Other intangible assets were $8.428B at September 30, 2025; 9M amortization was $513M versus $485M. Cash, cash equivalents and restricted cash totaled $4.349B, including $417M restricted cash. The company’s common shares issued declined from 672.163M at January 1 to 667.304M at September 30.

Financing, separation and restructuring

At September 30, short- and long-term borrowings totaled $7.446B. Corteva issued $700M of 6.00% senior notes due 2036; short-term borrowings included $3.078B under the PHI Bilateral Facility, $600M under a 364-day revolver and $183M of commercial paper. Corteva complied with its 0.60 debt-to-capitalization covenant. Following the October 1 Seed Business separation, Corteva used a $761M cash distribution to repay the $600M revolver balance and $161M of commercial paper. Vylor also repaid PHI bilateral borrowings using its new revolving facilities. Vylor’s October exchange of $1.439B principal amount of EIDP notes removed those notes as Corteva obligations.

The separation to publicly traded Vylor was completed October 1, after quarter-end. Corteva’s Crop Protection operations program had recorded $693M of expected aggregate charges of $750M–$815M through Q3, with $267M paid; expected cash payments are $400M–$443M, and actions are expected to be substantially complete by end-2028. A separate 2026 restructuring program had incurred $76M of charges, with expected charges and cash payments of $70M–$80M.

Legacy liabilities and other risks

Environmental obligations were $582M accrued at September 30, 2026, with $363M of indemnification assets and $581M of potential exposure above accruals. Management cautions that remediation costs could materially exceed accruals. Corteva and its legacy counterparties continue to face PFAS and other environmental litigation. Key developments included final approval of the New Jersey settlement ($875M over 25 years; estimated $500M net present value) and a North Carolina settlement totaling $455M over 15 years, of which Corteva’s share is approximately $66M. The North Carolina arrangement also requires a reserve/financial-assurance facility capped at $135M. Approximately 12,000 AFFF cases are consolidated in the South Carolina MDL, with the first personal-injury bellwether trial expected in 2027. A nationwide public-water-system settlement totaled $1.185B; approximately 93% of the settlement class remained in it.

Q3 discontinued-operations charges were $41M after tax, and 9M charges were $95M, primarily related to PFAS matters and the purchase of Chemours’ possible future interest in certain insurance proceeds. The Bayer dispute was resolved for $610M, paid by Q3, ending related litigation and disputed future royalty arrangements. Corteva also agreed to competition-related settlements without admitting wrongdoing; an accrual was established.**

Corteva (CTVA) — Q3 and nine months ended September 30, 2026

Consolidated results

Continuing-operations results reflected a weak third quarter but higher year-to-date operating EBITDA. Q3 sales declined on lower volume and price; 9M sales increased mainly from favorable currency, while volume and price were generally flat.

Q3 sales fell 6% as volume declined 6% and price 2%, partly offset by 2% favorable currency. COGS fell, reflecting lower volume and input costs and productivity actions. EBITDA weakness reflected Crop Protection pricing and volume pressure, higher IT and legal support fees, and increased R&D, partly offset by productivity, royalties and currency. In 9M, EBITDA benefited from Seed pricing and mix, royalties, lower input costs, productivity and currency, despite Crop Protection pricing pressure and higher IT/legal fees and R&D.

Diluted GAAP loss per share was $0.79 in Q3 versus $0.46; non-GAAP operating loss per share was $0.41 versus $0.23. For 9M, diluted GAAP EPS was $2.10 versus $2.54, while non-GAAP operating EPS rose to $3.39 from $3.11. Average diluted shares were 667.8M versus 678.7M in Q3 and 670.7M versus 683.1M in 9M. Non-GAAP results exclude specified items, including after-tax amortization of separation-era intangibles ($105M Q3; $345M 9M), significant-item charges ($66M; $266M), and separation costs ($86M; $193M). 9M also included $14M of after-tax foreign-currency contract mark-to-market losses.

The 9M tax provision was $479M on pretax income of $1.894B (25.3% effective rate), versus $477M on $2.218B (21.5%). The 2026 rate included $45M of separation-related charges and $50M related to a discretionary pension contribution, among other items, partly offset by tax benefits. Q3 recorded a $62M tax benefit on a $589M pretax loss. Discontinued-operations losses after tax were $41M in Q3 and $95M in 9M, versus $10M and $87M, primarily reflecting insurance-interest purchases, PFAS remediation and litigation.

Segment and regional sales

Segment operating EBITDA is a company-defined non-GAAP measure. Seed Q3 sales declined 1% as 11% lower volume was partly offset by higher price/mix and favorable currency; lower volume and higher IT/legal costs and R&D weighed on EBITDA. In 9M, Seed sales rose 4%, with gains in North America, EMEA and Latin America partly offset by an Asia Pacific decline; EBITDA benefited from pricing/mix, royalties and productivity. Crop Protection Q3 sales fell 9% on lower price/mix and volume, including competitive pricing in Latin America and weak Brazilian markets; its EBITDA declined on pricing and R&D pressure. In 9M, sales were down 1% and EBITDA essentially flat as pricing and cost pressures were offset by productivity and currency.

Latin American weakness reflected competitive pricing, weak Crop Protection markets and the shift to soybean out-licensing; currency partly offset declines. Asia Pacific Q3 weakness reflected lower Seed volumes and adverse currency, while dry weather affected 9M Seed volumes.

Cash flow, liquidity and capital returns

The larger continuing-operations cash outflow reflected a discretionary pension contribution, Bayer resolution payment, higher compensation payments and an FMC rimisoxafen prepayment, partly offset by improved collections. Investing outflow increased primarily due to a June 2026 acquisition; financing inflow rose as short-term borrowings funded working capital and other needs.

Debt increased substantially from year-end to fund separation-related financing, working capital and other corporate needs. Foreign subsidiaries held $2.1B of cash, generally used locally; repatriation may incur taxes. Corteva said liquidity was sufficient and was in compliance with its debt-to-total-capitalization covenant ceiling of 0.60. It issued $700M of 6.000% senior notes due 2036 in September. Vylor issued $1.1B of notes in August. After quarter-end, the Seed business separation was completed on October 1, 2026, through a pro rata distribution to Corteva shareholders, intended to be tax-free for U.S. federal income tax purposes. Separation-related credit facilities were refinanced, terminated or established for Corteva and Vylor; Vylor drew $1.578B and $1.5B under new revolvers to repay PHI’s bilateral facility.

Corteva returned approximately $860M to shareholders in 9M through repurchases and dividends. It repurchased 6.285M shares for $500M under its 2024 authorization and authorized three 2026 quarterly dividends of $0.18 per share (total $0.54 per share).

Actions and risks

The 2026 restructuring program recorded $76M of severance-related charges in 9M, with a $45M liability at September 30. Expected total charges are $70M–$80M, estimated annualized savings are $115M–$125M by 2027, and completion is expected by December 2026. Key exposures include agricultural demand and weather, Crop Protection pricing competition, input-cost and currency volatility, regulatory and product-development requirements, supply-chain and IT disruption, customer credit, and environmental and litigation liabilities. Separation execution also carries transition-service, unexpected-cost and litigation risks.

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

This section states that there was no material change in CTVA’s market-risk exposure. It provides no new quantitative sensitivity analysis or financial-instrument details, and refers readers to Note 15, “Financial Instruments,” in the interim consolidated financial statements and Item 7A of the 2025 Annual Report for discussion of the company’s financial instruments and sensitivity analysis.

Disclosure Controls and Procedures

As of September 30, 2026, Corteva’s CEO and CFO concluded, following management’s evaluation, that its disclosure controls and procedures were effective. No changes during Q3 2026 materially affected, or were reasonably likely to materially affect, Corteva’s internal control over financial reporting.

EIDP’s CEO and CFO likewise concluded that its disclosure controls and procedures were effective as of September 30, 2026. EIDP reported no Q3 2026 changes that materially affected, or were reasonably likely to materially affect, its internal control over financial reporting.

Corteva risk factors

Corteva’s principal risks involve regulatory access to its products, the pace and success of innovation, environmental and legal liabilities, supply-chain and market disruption, and the execution and consequences of the planned Vylor spin-off.

Regulation, innovation and competition

Crop-protection and seed products require costly testing, registrations and periodic renewals, often under changing or stricter standards. Delayed, denied or invalidated approvals could restrict sales and reduce returns on research and development. Requirements differ across jurisdictions, and residue findings may trigger recalls, crop destruction, export restrictions or trade disputes. Corteva also faces lawsuits seeking to invalidate pesticide registrations, including registrations for Enlist One®, and challenges to regulatory processes. Reduced staffing or funding at agencies such as the EPA, USDA, FDA and HHS, or shifts in agency priorities, could further slow reviews and commercialization.

Growth depends on developing and commercializing new products, but development is lengthy and only a small fraction of tested chemicals and biologicals reach commercialization. Projects may fail because of technical, cost, efficacy, regulatory or demand constraints; competitors are investing in similar products, and being first to market matters. Pest and weed resistance may develop faster than Corteva can respond. Public concerns about product safety, environmental effects, drift and resistance could delay approvals, reduce adoption or prompt litigation. Patent expirations, generic and “at-risk” launches, digital sales channels and greater price transparency may pressure product revenue and pricing. In 2026, Corteva entered into settlements with the FTC and several state attorneys general concerning customer loyalty program allegations, without admitting wrongdoing; continued scrutiny could bring costs, fines, restrictions or reputational harm.

Environmental, litigation and legacy exposures

Environmental rules, including those involving PFAS, could require additional operating costs, capital spending or facility changes. Contamination at current, former and divested-business sites may require remediation, and actual costs could exceed accruals. Corteva faces asserted and unasserted intellectual-property, commercial, product-liability, environmental and antitrust claims. Public-entity suits alleging harm to waterways, as well as negative sentiment associated with Roundup litigation, could contribute to claims against established products. Losses may exceed insurance coverage.

As of December 31, 2025, indemnification assets under the Chemours and Corteva Separation Agreements included $242 million in accounts and notes receivable, net, and $733 million in other assets (aggregate $975 million). Recovery depends on indemnitors’ ability and willingness to pay. Corteva has also assumed certain separation liabilities and agreed to uncapped indemnification of DuPont and Dow for specified matters, potentially including defense costs, settlements and judgments. Former parents or divested businesses may be unable or unwilling to honor indemnities, and third parties may seek to hold Corteva responsible for liabilities allocated elsewhere. Corteva could also face contingent tax liabilities for pre-separation tax periods if former parents do not pay amounts allocated to them.

Market, operational and financial exposures

Weather and climate affect pest pressure, product mix, demand, growing seasons and crop choices. Changes to farm subsidies or programs, including the U.S. Farm Bill, could weaken growers’ purchasing capacity. Raw-material and production costs fluctuate with global supply and demand. Corteva uses purchase contracts, derivatives, price increases and productivity or cost reductions to mitigate volatility, but competitive conditions may prevent it from fully passing higher costs through.

Conflict, trade barriers, tariffs, sanctions, logistics constraints, cyberattacks and currency volatility can disrupt supply, shipments, collections and operations. The Russia-Ukraine conflict has contributed to material shortages, higher transport, energy and raw-material costs, and shipment-insurance difficulties. A material portion of crop-protection inputs comes directly or indirectly from China; dual- and multi-sourcing may not be adequate in a China–Taiwan or broader conflict. Disruptions from suppliers, plants, power, transportation, weather or disease could raise costs or delay deliveries.

In 2025, Corteva’s sales outside the U.S. were principally to Brazil, Eurozone countries and Canada; major currency exposures include the Brazilian real, euro, Canadian dollar and Argentine peso. Inflation, weaker demand, exchange-rate changes, political instability and trade-policy shifts could affect sales, costs, earnings and cash flows. Corteva also relies on third parties for inputs, licenses, research, manufacturing and commercialization; their nonperformance or legal noncompliance could delay products or jeopardize important licenses.

Seasonal customer credit and financing programs can increase working-capital needs and short-term borrowing. Customer barter and financing arrangements generally run less than one year; poor harvests or economic weakness could impair customer repayment or delivery. Corteva generally guarantees customer credit in certain annually renewed financing programs, so reduced access or nonrenewal could weaken sales and increase borrowing needs. Downgrades could raise financing costs or limit access to capital markets.

Cyber incidents, including ransomware, employee error, sabotage or supplier breaches, could disrupt operations, expose confidential information or trade secrets, and cause legal or reputational harm. Espionage incidents have enabled unauthorized access to some confidential business information, although management does not believe material losses have occurred to date. Losses could exceed or fall outside insurance coverage. Counterfeit products likewise threaten customer safety, product integrity, sales and reputation; enforcement and Corteva’s mitigation efforts may not stop the problem.

Portfolio, pensions and Vylor spin-off

Acquisitions, strategic investments, biologicals initiatives and divestitures may fail to deliver expected growth, returns or savings. Corteva maintains EIDP defined-benefit pension and other post-employment plans, including responsibility for the entire principal U.S. pension plan regardless of participants’ connection to the agriculture business. No required contribution is anticipated for 2027, but future contributions could be significant if investment returns or other assumptions deteriorate. Failure to meet sustainability commitments, or shifts in public or investor sentiment, could also harm relationships, reputation, financing access or the stock price.

Corteva expects the Vylor spin-off to enable more tailored strategies and resource allocation, but the benefits are uncertain. As a smaller, less diversified standalone company, Corteva may be more exposed to industry-specific conditions. Historical and pro forma results may not reflect standalone costs or operations: integration with Seed provided economies of scale and scope, and transition services may not preserve those benefits. The separation also creates execution, financing, management and indemnity risks. If the distribution fails to qualify as tax-free, Corteva and shareholders could face significant taxes; a tax opinion does not prevent an IRS challenge. Tax-preservation rules may constrain acquisitions, share issuances and other strategic transactions.

Post-spin-off agreements could divert resources or result in liability if services are not performed. Corteva’s use of certain licensed intellectual property will be field-restricted, while Vylor controls its prosecution and maintenance and generally has the first right to enforce it. Weak protection or insufficient license coverage could raise development costs or hinder commercialization. Creditors could also challenge the spin-off or related reorganizations as fraudulent transfers, notwithstanding solvency opinions; later changes in environmental, litigation or other liabilities could increase that exposure.